



Q4 FY26: Revenue up by 23.6% Y-o-Y and EBITDA margin at 25.6%

Recommends dividend of 300%

Mumbai, 29 April 2026: RPG Life Sciences Limited has announced its financial results for the fourth quarter and for the financial year ended on 31 March, 2026.

Q4'26 Highlights

- a) *Revenue from operations grew by 23.6%, while maintaining healthy profitability*
- b) *Domestic Formulation (DF) recorded robust 18.2% growth, 1.8 times than market growth*
- c) *The API division demonstrated strong comeback and registered a growth of 144.3% in Q4 on the back of unit coming back to operations.*

FY'26 Highlights

- a) *Revenue from operations grew by 8.3% along with a healthy EBITDA margin of 24.4%*
- b) *DF, which contributes to 70% of overall sale, delivered market-beating 13.7% growth*
- c) *All major portfolio baskets recording healthy double-digit growths*

	Y-o-Y Revenue from operations
Q4 FY26 Highlights	Rs. 176.9 crores in Q4 FY26 vs. Rs. 143.1 crores in Q4 FY25
Full year FY26 Highlights	Rs. 707.5 crores in FY26 vs. Rs. 653.4 crores in FY25

In Q4 FY26, RPG Life Sciences recorded a 23.6% Y-o-Y increase in revenue, along with a healthy EBITDA margin of 25.6%. For FY26, revenue grew by 8.3%, maintaining operational momentum.

The Company has delivered a strong finish to the year with a healthy Q4 performance. In Q4, the Domestic Formulations (DF) business again delivered market-beating growth of 18.2% compared to the Indian Pharma Market (IPM), which grew by 10.1% in the same period; a 1.8 times growth placing us significantly ahead of the market. This has helped us become the 4th fastest growing pharma company in India.

For FY26, RPGLS DF business consistently outperformed market-growth by delivering 13.7% growth vs a modest 8.6% of IPM. This growth was driven by strong portfolio performance across our key therapy baskets like nephrology, oncology and pain management.

The API division demonstrated strong comeback and registered a growth of 144.3% in Q4 on the back of unit coming back to operations. The growth surge especially stands out considering the fire in our API manufacturing plant in January 2025 and the timely restoration of our facility.

Commenting on the results and the business outlook, Mr. Ashok Nair, Managing Director, RPG Life Sciences Ltd., said, "Overall, we have built solid momentum with healthy growth in Q4 and for the full fiscal year, driven by sharper field effectiveness, operational discipline and an unwavering focus on our key brands. The resilience demonstrated by our API business during the year reflects the strength of our teams and the robustness of our operations.

Looking ahead, we intend to strengthen our new product pipeline, sharpen equity of our existing brands, and drive field force effectiveness. We are also working towards widening our global footprint across fast-growing markets."

The Board of Directors at its meeting held today has recommended a Final dividend of Rs 24 per equity share i.e. 300% on the face value of Rs 8 each for FY25-26. This is subject to approval of shareholders.

RPG Life Sciences Ltd (www.rpglifesciences.com):

RPG Life Sciences is an integrated research-based pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company produces a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

RPG Group (www.rpggroup.com):

RPG Group, established in 1979, is one of India's fastest-growing business groups with a turnover of US\$ 5.2 billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation-led technology businesses.

Media Contact: Rashmi Menon – 88980 20577 | rashmi@rpg.in



An  **RPG** Company